Search Results - "Magee, Mindy H"

Effect of Ketoconazole on the Pharmacokinetic Profile of Ambrisentan by Richards, Duncan B., Walker, Gennyne A., Mandagere, Arun, Magee, Mindy H., Henderson, Linda S.

“…Ambrisentan is an endothelin type A (ETA)–selective receptor antagonist that is metabolized primarily by glucuronidation but also undergoes oxidative…”
Get full text

Safety, pharmacokinetics and pharmacological effects of the selective androgen receptor modulator, GSK2881078, in healthy men and postmenopausal women by Clark, Richard V., Walker, Ann C., Andrews, Susan, Turnbull, Philip, Wald, Jeffrey A., Magee, Mindy H.

“…Aim Selective androgen receptor modulators (SARMs) induce anabolic effects on muscle without the adverse effects of androgenic steroids. In this first‐in‐human…”
Get full text

Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study by Staurenghi, Giovanni, Ye, Li, Magee, Mindy H, Danis, Ronald P, Wurzelmann, John, Adamson, Peter, McLaughlin, Megan M

“…To investigate the potential of lipoprotein-associated phospholipase A2 inhibition as a novel mechanism to reduce edema and improve vision in center-involved…”
Get full text

Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans by Dave, Mehul, Nash, Mike, Young, Graeme C, Ellens, Harma, Magee, Mindy H, Roberts, Andrew D, Taylor, Maxine A, Greenhill, Robert W, Boyle, Gary W

“…The absorption, metabolism, and excretion of darapladib, a novel inhibitor of lipoprotein-associated phospholipase A2, was investigated in healthy male…”
Get full text

Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, in Diabetic Macular Edema by Staurenghi, Giovanni, MD, Ye, Li, MS, Magee, Mindy H., PhD, Danis, Ronald P., MD, Wurzelmann, John, MD, MPH, Adamson, Peter, PhD, McLaughlin, Megan M., MS

“…Purpose To investigate the potential of lipoprotein-associated phospholipase A2 inhibition as a novel mechanism to reduce edema and improve vision in…”
Get full text

Effects of Multiple Doses of Ambrisentan on the Pharmacokinetics of a Single Dose of Digoxin in Healthy Volunteers by Richards, Duncan B., Spence, Rebecca, Mandagere, Arun, Henderson, Linda S., Magee, Mindy H.

Get full text

Effects of Rifampicin (Rifampin) on the Pharmacokinetics and Safety of Ambrisentan in Healthy Subjects: A Single-Sequence, Open-Label Study by Harrison, Brooke, Magee, Mindy H., Mandagere, Arun, Walker, Gennyne, Dufton, Christopher, Henderson, Linda S., Boinpally, Ramesh

“…Background: Ambrisentan is a once-daily, endothelin (ET) type A receptor-selective antagonist approved for the treatment of pulmonary arterial hypertension…”
Get full text